Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. 1996

N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
Service des Maladies du Sang, Chu Angers.

Hodgkin's disease (HD) confined below the diaphragm accounts for less than 5% of all patients with HD. Although the major characteristics of this presentation appear established, optimal modalities of treatment still remain difficult to define. From April 1972 to October 1988, 28 patients with newly diagnosed infra-diaphragmatic HD, clinical stages I or II have been treated with 3 successive prospective protocols combining initial chemotherapy and radiotherapy (40 gy). This series of patients accounted for 4,3% of patients with HD limited to clinical stages (CS) I and II. Overall survival and freedom from relapse at 15 years were 74,4% and 73% respectively, without significant differences between clinical stages I and II, presence or absence of B symptoms or histologic subtype. There is only a trend (p < 0,10) in favour of patients younger than 40 years. In all 7 clinically staged IA patients no relapses were seen and combined treatment does not appear to be better than inverted Y irradiation alone. On the other hand initial chemotherapy seems necessary in patients with CS II A and B since 15 of our 21 patients are alive in first CR whereas the crude rate of transdiaphragmatic nodal relapses may reach up to 53% following radiotherapy alone.

UI MeSH Term Description Entries
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008297 Male Males
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
March 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
April 1982, Cancer treatment reports,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
June 1976, Cancer,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
February 1991, Australian and New Zealand journal of medicine,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
January 2003, International journal of radiation oncology, biology, physics,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
December 1999, International journal of radiation oncology, biology, physics,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
December 2004, Clinical breast cancer,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
January 1997, Haematologia,
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
January 1992, European journal of cancer (Oxford, England : 1990),
N Ifrah, and M Hunault, and J P Jais, and P Moreau, and B Desablens, and P Casassus, and J Briere, and C Le Maignan, and J M Andrieu
January 1992, Frontiers of radiation therapy and oncology,
Copied contents to your clipboard!